| Name | Title | Contact Details |
|---|---|---|
Dan Golden |
Vice President, Information Systems | Profile |
Andrew Neumann |
Chief Information Officer | Profile |
Dev Ashish |
Chief Information Officer | Profile |
Midland Care Connection is a not-for-profit, community-based organization that provides a variety of health and aging care solutions, including end-of-life care, palliative care, bereavement care, and frail elder care services.
Endocare is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Endocare is based in Irvine, CA. You can find more information on Endocare at www.endocare.com
Avanti Hospitals currently owns and operates four acute care hospitals: East Los Angeles Doctors Hospital, Memorial Hospital of Gardena, Community Hospital of Huntington Park, and Coast Plaza Hospital, all located near Los Angeles, California. Our mission is to provide affordable, high quality healthcare services to our community with consistency and compassion. Avanti is committed to cooperating with and supporting the long-term needs and objectives of each community we serve. We understand the impact we have on our communities and the potential to improve overall health. We have worked hard to establish a reputation of quality and trust in our communities, including local physicians and governments. At each of our hospitals, we seek to implement community support through a variety of initiatives that are specific to each individual community. With nearly 2,000 employees and over 775 physicians, the Avanti team is committed to delivering the highest quality care to our patients through a broad range of medical services. We also continue to add new programs and technology to meet the meet the growing needs of the communities we serve.
Carenet Health is a leading provider of healthcare consumer engagement solutions, clinical support, health advocacy and navigation solutions, and 24/7 access to medical care. Our engagement specialists, care coordinators and registered nurses support 1 in 4 Americans (more than 86 million healthcare consumers) on behalf of 250+ of the nation`s premier health plans, providers, health systems and Fortune 500 organizations. Our mission is to drive market-leading consumer engagement outcomes through our proprietary Intelligent Engagement model. Our best-practice solutions are delivered by outstanding teams and backed by clinical capital, data and technology, operational excellence and expertise from outside of healthcare. Every day, our team members guide people to high-quality and cost-effective care, and coach them to close gaps in care and improve their health. For eight consecutive years, Inc. Magazine named Carenet as one of America`s fastest-growing private companies.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.